

#13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. National Phase of
PCT/EP 00/00637 of:

Walter Sebald

Application No.: Not yet assigned

Filed: Herewith

For: POLYPEPTIDE VARIANTS WITH
INCREASED HEPARIN-BINDING
ABILITY

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

San Francisco, CA 94111
August 13, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached forms PTO-SB/08A and PTO-SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. In addition, applicant encloses a copy of an International Search Report (with English translation) dated August 17, 2000, which was issued in conjunction with the above referenced international application.

Please note that copies of the references cited therein are not being provided pursuant to MPEP 1893.03(g), but will be provided under separate cover later if the Examiner requests it.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
ASP/dxm

SF 1257447 v1

FORM PTO-1449 (Modified)			Attorney Docket No.: 086033-00900913457			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Application No.: PCT/EP 00/00637			
			Applicant: Walter Sebald		Group: Unassigned	
Filing Date: Herewith						
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
___ AA						
___ AB						
___ AC						
___ AD						
___ AE						
___ AF						
___ AG						
___ AH						
___ AI						
___ AJ						
___ AK						
___ AL						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
___ AM						
___ AN						
___ AO						
___ AP						
___ AQ						
___ AR						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
___ AS						
___ AT						
___ AU						
___ AV						
___ AW						
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	<u> / / </u>
				First Named Inventor	Sebald , Walter
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	086033-000000US
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	12	PCT	WO 96/39430		Hall, et al.	12/12/96		<input type="checkbox"/>
	13	PCT	WO 97/06254		Biopharm Gesellschaft	02/20/97		<input type="checkbox"/>
	14	PCT	WO 97/47312	A	Commw. Biotechnologies Inc.	12/18/97		<input type="checkbox"/>
	15	EP	0 414 915	A	Suntory Ltd; Inque Masayasu	03/06/91		<input type="checkbox"/>
	16	PCT	WO 91/18558	A	Creative Biomolecules Inc.	12/12/91		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this



533 Rec'd PCT/PTO 13 AUG 2001
09/3467 PTO/SB/08B (08-00) +

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Filing Date	__/__/__
				First Named Inventor	Sebald, Walter
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	086033-000000US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
								<input type="checkbox"/>
OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T ²
	17	Jay Gropp, et al.: "Biochemical and Biophysical Characterization of Refolded <i>Drosophila</i> DPP, a Homolog of Bone Morphogenetic Proteins 2 and 4" <i>Journal of Biochemistry</i> , Vol. 273 (44) October 30, 1998, pp. 29052-29065						<input type="checkbox"/>
	18	N. R. Küber, et al.: "Inductive properties of recombinant human BMP-2 produced in bacterial expression system," <i>Intl. Journal of Oral Maxillofacial Surgery</i> , (08/98), Vol. 27 (4) pp. 305-309						<input type="checkbox"/>
	19	R. Ruppert, et al.: "Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity" <i>Eur. J. Biochem.</i> Vol. 237 (1996) pp. 295-302						<input type="checkbox"/>
	20	J.R. From, et al.: "Differences in the interaction of heparin with arginine and lysine and the importance of the basic amino acids in the binding heparin to acidic fibroblast growth factor" <i>Archives of Biochemistry and Biophysics</i> , Vol. 323(2), November 10, 1995, pp. 279-287						<input type="checkbox"/>
	21	E. Albert, et al.: "Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site" Vol. 37 (1998) pp. 10643-40652						<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1257532 v1